Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 19;30(10):9230-9243.
doi: 10.3390/curroncol30100667.

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Sara Mheid  1 , Stefan Allen  2 , Sylvia S W Ng  3 , William A Hall  4 , Nina N Sanford  5 , Todd A Aguilera  5 , Ahmed M Elamir  5 , Rana Bahij  6 , Martijn P W Intven  7 , Ganesh Radhakrishna  8 , Issa Mohamad  9 , Jeremy De Leon  10 , Hendrick Tan  11   12 , Shirley Lewis  13 , Cihan Gani  14 , Teo Stanecu  1 , Veronica Dell'Acqua  15 , Ali Hosni  1
Affiliations
Review

Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century

Sara Mheid et al. Curr Oncol. .

Abstract

The utilization of stereotactic body radiation therapy for the treatment of liver metastasis has been widely studied and has demonstrated favorable local control outcomes. However, several predictive factors play a crucial role in the efficacy of stereotactic body radiation therapy, such as the number and size (volume) of metastatic liver lesions, the primary tumor site (histology), molecular biomarkers (e.g., KRAS and TP53 mutation), the use of systemic therapy prior to SBRT, the radiation dose, and the use of advanced technology and organ motion management during SBRT. These prognostic factors need to be considered when clinical trials are designed to evaluate the efficacy of SBRT for liver metastases.

Keywords: SBRT; liver; oligometastases.

PubMed Disclaimer

Conflict of interest statement

Ali Hosni: non-financial leadership, DSC of liver TSG at ELEKTA MRL consortium.

References

    1. Almaghrabi M.Y., Supiot S., Paris F., Mahé M.-A., Rio E. Stereotactic body radiation therapy for abdominal oligometastases: A biological and clinical review. Radiat. Oncol. 2012;7:126. doi: 10.1186/1748-717X-7-126. - DOI - PMC - PubMed
    1. Rusthoven K.E., Kavanagh B.D., Cardenes H., Stieber V.W., Burri S.H., Feigenberg S.J., Chidel M.A., Pugh T.J., Franklin W., Kane M., et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009;27:1572–1578. doi: 10.1200/JCO.2008.19.6329. - DOI - PubMed
    1. Adam R., De Gramont A., Figueras J., Guthrie A., Kokudo N., Kunstlinger F., Loyer E., Poston G., Rougier P., Rubbia-Brandt L., et al. The Oncosurgery Approach to Managing Liver Metastases from Colorectal Cancer: A Multidisciplinary International Consensus. Oncologist. 2012;17:1225–1239. doi: 10.1634/theoncologist.2012-0121. - DOI - PMC - PubMed
    1. Horn S.R., Stoltzfus K.C., Lehrer E.J., Dawson L.A., Tchelebi L., Gusani N.J., Sharma N.K., Chen H., Trifiletti D.M., Zaorsky N.G. Epidemiology of liver metastases. Cancer Epidemiol. 2020;67:101760. doi: 10.1016/j.canep.2020.101760. - DOI - PubMed
    1. Hellman S., Weichselbaum R.R. Oligometastases. J. Clin. Oncol. 1995;13:8–10. doi: 10.1200/JCO.1995.13.1.8. - DOI - PubMed